Societal Color Logo and Tagline.png
Societal CDMO to Report Financial Results for First Quarter 2022 on May 11, 2022
May 04, 2022 16:05 ET | Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., May 04, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO)...
logo.png
Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)
January 04, 2022 07:25 ET | Arch Biopartners
TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug...
logo.png
Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial
December 01, 2021 07:35 ET | Arch Biopartners
LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which is common in moderate to severe cases of COVID-19, regardless of variant...
Axtria Leads Discuss
Axtria Leads Discussion on Pharma’s Advanced Uses of Data Analytics and Artificial Intelligence With 6 Sessions at PMSA 2021 Annual Conference
June 16, 2021 08:00 ET | Axtria Inc.
Berkeley Heights, NJ, June 16, 2021 (GLOBE NEWSWIRE) -- With the elevated importance of data analytics and artificial intelligence (AI)-driven intelligence technology systems for a global life...
logo-alt.png
Rheumatic Fever Treatment Market is estimated with a CAGR of 5.2% during the forecast period - by PMI
June 11, 2021 10:35 ET | PMI
Covina, CA, June 11, 2021 (GLOBE NEWSWIRE) -- Rheumatic Fever Treatment Market is estimated with a CAGR of 5.2% during the forecast period. Rheumatic fever is an infectious inflammatory condition...
logo.png
Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation
June 10, 2021 07:20 ET | Arch Biopartners
TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
logo.png
Arch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19
May 04, 2021 07:00 ET | Arch Biopartners
TORONTO, May 04, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
logo-alt.png
Global Thalassemia Treatment Market is estimated to be US$ 14.7 billion by 2030 with a CAGR of 10.40% during the forecast period - By PMI
April 30, 2021 10:05 ET | PMI
Covina, CA, April 30, 2021 (GLOBE NEWSWIRE) -- The Global Thalassemia Treatment Market accounted for US$ 2.3 billion in 2020 and is estimated to be US$ 14.7 billion by 2030 and is anticipated to...
new logo.jpg
Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy
April 07, 2021 08:00 ET | Immutep Limited
Sydney, AUSTRALIA, April 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
ASC_logo_black.jpg
Appointment of Ben Vertannes as Head of Global Marketing
March 08, 2021 02:00 ET | Ascension
PRESS RELEASE Appointment of Ben Vertannes as Head of Global Marketing LONDON, March 8, 2021 – Ascension Healthcare plc (“Ascension” or the “Company”), a clinical-stage pharmaceutical company...